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A Control Switch for Prothrombinase
CHARACTERIZATION OF A HIRUDIN-LIKE PENTAPEPTIDE FROM THE COOH TERMINUS OF
FACTOR Va HEAVY CHAIN THAT REGULATES THE RATE AND PATHWAY FOR
PROTHROMBIN ACTIVATION *
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Membrane-bound factor Xa alone catalyzes prothrombin
activation following initial cleavage at Arg271 and prethrombin 2
formation (pre2 pathway). Factor Va directs prothrombin activation by factor Xa through the meizothrombin pathway, characterized by initial cleavage at Arg320 (meizo pathway). We have
shown previously that a pentapeptide encompassing amino acid
sequence 695– 699 from the COOH terminus of the heavy chain
of factor Va (Asp-Tyr-Asp-Tyr-Gln, DYDYQ) inhibits prothrombin activation by prothrombinase in a competitive manner with respect to substrate. To understand the mechanism of
inhibition of thrombin formation by DYDYQ, we have studied
prothrombin activation by gel electrophoresis. Titration of plasma-derived prothrombin activation by prothrombinase, with
increasing concentrations of peptide, resulted in complete inhibition of the meizo pathway. However, thrombin formation still
occurred through the pre2 pathway. These data demonstrate
that the peptide preferentially inhibits initial cleavage of prothrombin by prothrombinase at Arg320. These findings were
corroborated by studying the activation of recombinant mutant
prothrombin molecules rMZ-II (R155A/R284A/R271A) and
rP2-II (R155A/R284A/R320A) which can be only cleaved at
Arg320 and Arg271, respectively. Cleavage of rMZ-II by prothrombinase was completely inhibited by low concentrations
of DYDYQ, whereas high concentrations of pentapeptide
were required to inhibit cleavage of rP2-II. The pentapeptide
also interfered with prothrombin cleavage by membranebound factor Xa alone in the absence of factor Va increasing
the rate for cleavage at Arg271 of plasma-derived prothrombin or rP2-II. Our data demonstrate that pentapeptide
DYDYQ has opposing effects on membrane-bound factor Xa
for prothrombin cleavage, depending on the incorporation of
factor Va in prothrombinase.
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Prothrombinase is the enzymatic complex responsible for
timely thrombin formation in response to vascular injury (1, 2).
Activation of human prothrombin is the consequence of two
cleavages at Arg271 and Arg320 in prothrombin by factor Xa.
Depending on the order of peptide bond cleavage, different
intermediates are formed (Fig. 1). Cleavage first at Arg271 produces fragment 1䡠2 and prethrombin-2, whereas initial cleavage
at Arg320 results in the formation of meizothrombin, which has
enzymatic activity (3–14). Whereas factor Xa alone can activate
prothrombin following sequential cleavages at Arg271 and
Arg320 to produce thrombin (Fig. 1, pathway I, pre2 pathway),
its catalytic efficiency is poor in the absence of factor Va, and
the overall reaction is incompatible with survival and the rapid
arrest of bleeding. The prothrombinase complex, which is
formed following the interaction of factor Va with membranebound factor Xa in the presence of divalent metal ions, catalyzes
the activation of prothrombin following the opposite pathway
(Arg320 followed by Arg271; see Fig. 1, pathway II, meizo pathway), resulting in a substantial increase in the catalytic efficiency of factor Xa required for normal hemostasis (15).
Although both cleavages are phospholipid-dependent, only initial cleavage of prothrombin at Arg320 is strictly dependent on
factor Va. The increase in the rate of the overall enzymatic
reaction is attributed to an increase in the kcat, which in turn is
solely credited to the interaction of the cofactor molecule with
both the membrane-bound enzyme and the membrane-bound
substrate (11–18). Thus, the activity of prothrombinase is limited and controlled by the presence of the soluble, nonenzymatic cofactor factor Va.
Proteolytic processing of factor V by ␣-thrombin at Arg709,
Arg1018, and Arg1545, resulting in the production of the active
cofactor factor Va, which consists of a heavy chain (Mr 105,000)
and a light chain (Mr 74,000), is required for the interaction of
the cofactor with the members of prothrombinase (19 –21).
Factor Va heavy chain has an acidic hirudin-like region at the
COOH terminus that has been implicated in cofactor activity
(22–24). This region contains tyrosine residues that have the
potential to be sulfated and have been reported to be important
for both factor V activation by ␣-thrombin and cofactor function (23, 24).
Prothrombin and ␣-thrombin have two discrete electropositive binding exosites (anion-binding exosite I (ABE-I) and
anion-binding exosite II (ABE-II)) that are responsible for the
functions of the molecules (25–35). Proexosite I of prothromVOLUME 281 • NUMBER 51 • DECEMBER 22, 2006
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FIGURE 1. Schematic of the two pathways for the activation of human
prothrombin. Two factor Xa-catalyzed cleavages convert prothrombin to
thrombin. Initial cleavage at Arg271 by membrane-bound factor Xa in the
absence of factor Va results in the generation of fragment 1䡠2 and prethrombin 2. Subsequent cleavage at Arg320 results in thrombin formation (pathway
I, pre2 pathway). Initial cleavage at Arg320 by prothrombinase (factor Va
bound to factor Xa on a membrane surface in the presence of Ca2⫹) results in
the production of an enzymatically active intermediate (meizothrombin).
Cleavage of this intermediate at Arg271 produces thrombin and fragment 1䡠2
(pathway II, meizo pathway). Thrombin also cleaves prothrombin at Arg155
and at Arg284 (dashed arrows).

bin, which is present in a low affinity state on the molecule, is
fully exposed following activation and formation of thrombin,
and the affinity for its ligands increases by ⬃100-fold (36). The
procofactor, factor V, interacts with immobilized ␣-thrombin
but with a lower affinity than factor Va (25, 27). Finally, it has
been repetitively shown by several laboratories that the role of
ABE-I in prothrombinase is dependent on the incorporation of
factor Va into the complex (28, 36 –39).
We have recently identified a pentapeptide from the COOH
terminus of the heavy chain of the cofactor (spanning amino
acid residues 695– 699, DYDYQ) as potent inhibitor of prothrombinase function (40). The peptide was found to be a competitive inhibitor of prothrombinase with respect to substrate.
According to the mode of inhibition, we postulated that the
peptide binds prothrombin in competition with the binding of
the substrate to the enzyme and inhibits prothrombinase activity by substrate depletion. This mode of DYDYQ inhibition of
prothrombin activation by the factor Va-factor Xa complex is
similar to that demonstrated previously for sulfated hirugen
(28). This uncommon mode of inhibition (41, 42) is an accepted
mechanism of regulation of phospholipase A2 by annexin 1
(lipocortin 1) (43, 44), as well as for the regulation of other
important physiological processes (44 – 46). The present work
was undertaken to elucidate the molecular mechanism underlying the inhibition of prothrombin activation by DYDYQ.

EXPERIMENTAL PROCEDURES
Materials, Reagents, and Proteins—L-␣-Phosphatidylserine
(PS)2 and L-␣-phosphatidylcholine (PC) were from Avanti
2

The abbreviations used are: PS, L-␣-phosphatidylserine; PC, L-␣-phosphatidylcholine; HPLC, high performance liquid chromatography; rMZ-II, (pro-
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Polar Lipids (Alabaster, AL). The chromogenic substrate Spectrozyme-TH was from American Diagnostica, Inc. (Greenwich,
CT). Human ␣-thrombin and human prothrombin were from
Hematologic Technologies, Inc. (Essex Junction, VT). The
monoclonal antibody ␣hFV1 coupled to Sepharose was provided by Dr. Kenneth G. Mann (Department of Biochemistry,
University of Vermont, Burlington, VT). Human factor Xa was
from Enzyme Research Laboratories (South Bend, IN).
The pentapeptide DYDYQ that was previously shown to
inhibit prothrombinase activity and delay factor V activation
(40) was custom-synthesized under the form H2N-DYDYQamide and purchased from New England Peptide, Inc. (Gardner, MA) and from American Peptide Co. (Sunnyvale, CA). In
each case, the peptide was purified by HPLC to more than 96%
homogeneity. Its molecular weight and composition were usually verified by mass spectrometry and amino acid composition
analysis, respectively. DYDYQ is a highly negatively charged
peptide, and all mass spectrometry analysis was conducted in a
negative mode. The peptide was stored lyophilized at ⫺20 °C in
a dessicator. It is noteworthy that significant solubility problems were encountered when using the peptide. DYDYQ was
insoluble at concentrations higher than 5 mM in water or in the
assay buffer. DYDYQ at high concentrations slowly precipitated when incubated in an ice bucket, resulting in a gelatinous
insoluble mass. Thus, for all experiments DYDYQ was made
fresh in Milli Q (Millipore Corp., Bedford, MA) water at concentrations ranging between 2 and 4 mg/ml and kept at room
temperature. DYDYQ was also frozen in small aliquots. All frozen peptide aliquots were thawed and used only once. Peptide
solutions were always centrifuged prior to use to remove potential microaggregates and insoluble material. After the peptide
was dissolved in water or buffer, the molar concentration of
DYDYQ was initially calculated to a theoretical concentration
assuming the degree of purity specified by the supplier and
100% peptide content. However, because DYDYQ is a highly
negatively charged pentapeptide, theoretically it could adsorb
water and counter ions during HPLC purification. Invariably,
significant amounts of salt were present in the initial lyophilized, purified peptide preparations obtained from the manufacturers and used in this study. Thus, the exact concentration
of each peptide solution used and provided throughout this
study was determined following amino acid composition analysis of an aliquot in the laboratory of Dr. Alex Kurosky and
Steve Smith (University of Texas Medical Branch, Galveston).
Briefly, peptide samples were centrifuged for 5 min at 16,000
rpm to remove any precipitation that might be present in the
tube. 10 l of each supernatant was placed in a Wheaton 1-ml
pre-scored vacule and dried (a vacule is a small thin-walled glass
vial with a long neck that can be sealed with a torch while a
vacuum is being applied). 100 l of 6 N constant boiling HCl was
added to each vacule. The vacules were sealed with a torch
under vacuum and hydrolyzed for 20 h at 107 °C. After hydrol-

thrombin with the substitutions R155A, R284A, and R271A); rP2-II, (prothrombin with the substitution R155A, R284A, and R320A); ABE-I, anion
binding exosite I; ABE-II, anion binding exosite II; DYDYQ, pentapeptide
mimicking factor Va heavy chain sequence: Asp695–Tyr696–Asp697–Tyr698–
Gln699; DAPA, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amine.
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ysis the vacules were dried, and the contents were resuspended
in 40 l of 0.02 N HCl. 10 l of each sample was subsequently
injected into a Hitachi L-8800 amino acid analyzer. Average
concentration (micromoles/ml) was determined by data analysis using the Hitachi L-8800 AAA System Manager. The
mole/ml values obtained directly from the analyzer for each
amino acid were multiplied by the molecular weight of the peptide (Mr 702) to determine the milligram/ml of peptide.
Because of the harsh conditions of hydrolysis, the mole values
found for Tyr were not taken into account for the determination of the final peptide concentrations. It is noteworthy that for
each analysis, the average mole numbers of Asp divided by 2
was usually very close to the total mole number obtained with
Gln, confirming the accuracy of the method. Usually the mole
values obtained with Asp and Gln were averaged to obtain the
exact concentration of peptide. This method determines the
concentration of a peptide solution with an accuracy of 96 ⫾
6%. Under these conditions, the calculated starting concentration of peptide in each experiment was systematically found to
be lower than its initial concentration calculated after the peptide was dissolved in water or buffer. It is important to note that
in order to verify peptide bond integrity of DYDYQ during storage, several peptide solutions used in this study were randomly
analyzed by NH2-terminal sequence analysis in the same laboratory. Again, significant problems were encountered when
attempting to sequence DYDYQ using the traditional method
(polyvinylidene difluoride sample support). Under these conditions, the yield of amino acid per cycle was low as most of the
peptide was washed off the polyvinylidene difluoride sample
support. NH2-terminal sequencing of DYDYQ was thus performed on a Biobrene PlusTM-treated glass fiber filter sample
support (Applied Biosystems, Foster City, CA.). Biobrene Plus
is a cationic polymer used to immobilize peptide and protein
samples on the glass fiber filter during Edman degradation. A
much higher yield of amino acids per cycle was observed using
these conditions. NH2-terminal sequencing demonstrated that
the majority of peptide remained intact following extensive
incubation periods.
Recombinant prothrombin rMZ-II and rP2-II that have only
one cleavage site for factor Xa were prepared and purified as
described (47– 49). Human factor V was purified using methodologies previously described employing the monoclonal antibody ␣hFV1 coupled to Sepharose (50) and activated to factor
Va with thrombin as described recently (51). Phospholipid vesicles composed of 75% PC and 25% PS (referred to as PCPS
vesicles throughout the study) were prepared as described previously (52).
Assay Measuring Thrombin Formation—Initial experiments
performed to identify the best conditions allowing peptide inhibition of prothrombin activation revealed that preincubation of
prothrombin with DYDYQ in a small volume is required to
observe maximum inhibition of prothrombinase activity by the
peptide. Thus, the ability of the peptide to inhibit prothrombin
activation by either prothrombinase or factor Xa alone was
conducted exactly as follows. In a typical experiment, a constant concentration of prothrombin was preincubated with
increasing concentrations of peptide at room temperature in a
15-l volume. Following a 10-min incubation period, the pro-
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thrombin/peptide sample was centrifuged, and the entire mixture was added to different tubes containing a solution composed of PCPS vesicles (1 or 10 M), DAPA (50 M), and factor
Va (1–5 nM) in the presence of 5 mM Ca2⫹ in 20 mM HEPES,
0.15 M NaCl, pH 7.4. The reaction was started by the addition of
factor Xa (0.5 nM) at room temperature. The final concentration of prothrombin was 1.4 M or 300 nM, whereas the final
concentration of peptide is provided in the text. All final concentrations of reagents provided in the text and relating to the
measure of activity of prothrombinase in the presence or
absence of peptide were calculated assuming a final reaction
volume of 225 l. At selected time intervals, aliquots of the
mixture were diluted 2-fold in a buffer containing EDTA (50
mM) to quench the reaction. The assay verifying thrombin formation was conducted as described by measuring the initial
rate of thrombin formation by the change in the absorbance of
a chromogenic substrate at 405 nm (Spectrozyme-TH) monitored with a Thermomax microplate reader (Molecular
Devices, Sunnyvale, CA) (51). Percent inhibition of thrombin
generation was calculated by comparing the initial rates of
thrombin formation obtained in the presence of peptide with
the control reaction in the absence of peptide.
Inhibition of Prothrombin Cleavage by DYDYQ and Analysis
of Prothrombin Activation by Gel Electrophoresis—Initial preliminary experiments carried out to determine the optimum
conditions necessary to observe the effect of DYDYQ on prothrombin activation by prothrombinase by gel electrophoresis
established that the best results (maximum inhibition) are
obtained when the peptide is preincubated with prothrombin
in a small volume. Thus, all samples analyzed by gel electrophoresis examining the effect of DYDYQ on prothrombin activation were prepared precisely as follows. In a typical experiment, plasma-derived prothrombin or recombinant mutant
prothrombin at a constant concentration were preincubated
with varying (increasing) concentrations of DYDYQ for 10 min
in a 50-l volume. Following centrifugation, the entire supernatant containing the prothrombin/peptide mixture was added
to separated solutions containing PCPS vesicles (1 or 10 M),
DAPA (50 M), and factor Va (1–5 nM) in the presence of 5 mM
Ca2⫹ in 20 mM Tris, 0.15 M NaCl, pH 7.4. The reaction was
started by the addition of factor Xa (0.5 nM) at room temperature. The final volume of each reaction mixture was 1,200 l
when the prothrombin concentration was 1.4 M. The final
concentration of DYDYQ reported throughout the study in
experiments studying prothrombin activation by gel electrophoresis was always calculated using the final volume of the
reaction mixture. The effect of the peptide on prothrombin
activation by factor Xa alone (in the absence of factor Va) was
studied in a similar manner (preincubation of prothrombin and
peptide in a 50-l volume for 10 min). The reaction was started
by the addition of factor Xa. The final concentrations of
reagents in this case were as follows: 2.5–5 nM enzyme, 1.4 M
prothrombin, and 50 M PCPS in a final volume of 1,200 l.
Control experiments studying activation of prothrombin by
factor Xa alone in the absence of factor Va and phospholipid
were also performed in a similar fashion. At selected time intervals (indicated in the figure legends), aliquots from the reaction
mixtures (60 l) were removed and immediately diluted into 2
VOLUME 281 • NUMBER 51 • DECEMBER 22, 2006
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volumes of 0.2 M glacial acetic acid and concentrated using a
Centrivap concentrator attached to a Centrivap cold trap
(Labconco Corp., Kansas City, MO). The dried samples were
dissolved in 0.1 M Tris base, pH 6.8, 1% SDS (final concentration), 1% ␤-mercaptoethanol (final concentration), heated for
exactly 65 s at 90 °C, mixed again, and subjected to SDS-PAGE
using 9.5% gels according to the method of Laemmli (53). Usually 6 g of total protein per lane were applied. Protein bands
were visualized following staining by Coomassie Brilliant Blue
R-250 and destained in a methanol/acetic acid/water solution.
After each experiment using a new peptide solution, an aliquot
of the solution was stored at ⫺20 °C. Following amino acid

FIGURE 2. Inhibition of prothrombinase function by DYDYQ. Plasma-derived prothrombin (1.4 M final concentrations) was preincubated with various concentrations of peptide DYDYQ shown on the x axis. The rate of thrombin formation by prothrombinase was assessed as described under
“Experimental Procedures” and compared with the rate of thrombin formation determined in a control reaction in the absence of peptide. The data represent the average of the results found in three independent measurements.

composition analysis, the exact initial concentration of each
peptide solution was calculated for every experiment. The final
concentration of peptide used was then back-calculated and is
reported throughout the study. Finally, it is worth mentioning
that despite all the problems encountered when working with
DYDYQ, using the precise experimental protocol provided
above, highly reproducible results were observed with 18 separate peptide preparations from two different suppliers (New
England Peptide, Inc. and American Peptide Co.) representing
three different batches of peptide.
Scanning Densitometry of SDS-PAGE and Calculation of the
Rate of Prothrombin Consumption—Scanning densitometry of
the gels was performed as described earlier (54) and recently
with several modifications (51). The stained gels were scanned
with a Lexmark printer/scanner; the final images were
imported into Adobe Photoshop, captured as TIFF files, and
subsequently imported into the software UN-SCAN-IT gel
(Silk Scientific, Orem, UT). Following analysis, the numerical
data were saved as a Microsoft Excel file, and the molar concentration of prothrombin as observed on the gels was calculated
by normalizing its staining intensity to the initial prothrombin
concentration. The data representing prothrombin consumption as a function of time (seconds) were subsequently plotted
according to the equation representing a first-order exponential decay using the software Prizm (GraphPad, San Diego). The
apparent first-order rate constant, k (s⫺1), obtained directly
from the graph was subsequently divided by the molar concentration of factor Xa used in each experiment (to obtain s⫺1 ⫻
molar factor Xa⫺1). The number obtained was subsequently
multiplied by the starting concentration of prothrombin used
(1.4 M or 300 nM). The final numbers reported throughout the
study, characterizing the effect of DYDYQ on prothrombin
cleavage by either prothrombinase or factor Xa alone, represent
moles of prothrombin consumed
per mol of factor Xa/s for a given
experiment. All numbers reported
in the study are representative of
experiments performed at least in
triplicate using 3– 4 different peptide preparations.

FIGURE 3. Analysis of the activation of plasma-derived prothrombin by prothrombinase in the absence
and presence of DYDYQ. Plasma-derived prothrombin (300 nM) was preincubated with buffer or a peptide
solution. The mixture was then added to a solution containing PCPS vesicles, DAPA, and plasma factor Va as
described under “Experimental Procedures.” The reaction was started by the addition of factor Xa. At selected
time intervals, aliquots of the reactions were withdrawn and treated as described under the “Experimental
Procedures.” M represents the lane with the molecular weight markers (from top to bottom): Mr 98,000, Mr
64,000, Mr 50,000, Mr 36,000, and Mr 22,000. Lanes 1–19 represent samples from the reaction mixture before (0
min) the addition of factor Xa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, and 240 s and 5, 6, 10, 20, 30,
and 60 min, respectively, following the addition of factor Xa. Panel A control, prothrombinase assembled with
plasma-derived factor Va in the absence of peptide; panel B, prothrombinase in the presence of 20 M DYDYQ.
The prothrombin-derived fragments are shown as follows: II, prothrombin (amino acid residues 1–579); F1䡠2-A,
fragment 1䡠2-A chain (amino acid residues 1–320); F1䡠2, fragment 1䡠2 (amino acid residues 1–271); P2, prethrombin-2 (amino acid residues 272–579); B, B chain of thrombin (amino acid residues 321–579).

DECEMBER 22, 2006 • VOLUME 281 • NUMBER 51

RESULTS
Effect of DYDYQ on the Pathway
for Prothrombin Activation—We
have shown previously that a pentapeptide containing amino acids
695– 699 from the COOH terminus
of factor Va heavy chain (Asp-TyrAsp-Tyr-Gln, DYDYQ) is a competitive inhibitor of prothrombinase
with respect to the substrate, prothrombin (40). To ascertain the
mechanism of inhibition of prothrombinase by DYDYQ, we have
studied prothrombin activation by
gel electrophoresis. Fig. 2 shows
50% inhibition of prothrombinase
activity in the presence of 7.5 M
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20 M peptide (Fig. 3, panel B), no
meizothrombin is evident as established by the lack of fragment 1䡠2-A.
However, thrombin formation still
occurs, as verified by the appearance of the B chain of thrombin,
albeit with a considerably delayed
rate, following the pre2 pathway as
established by the presence of prethrombin 2. These data suggest that
under the conditions employed
DYDYQ selectively inhibits cleavage at Arg320 by prothrombinase
and favors initial cleavage of prothrombin at Arg271. This conclusion
is inferred from the lack of meizothrombin and the increase in the
concentration of prethrombin 2,
both of which are the expected consequences of selective inhibition of
cleavage of prothrombin by proFIGURE 4. Analysis of the activation of plasma-derived prothrombin by prothrombinase in the presence
320
of increasing concentrations of DYDYQ. Plasma-derived prothrombin (300 nM) was preincubated with thrombinase at Arg .
To
determine
at
what peptide
buffer or several different peptide solutions and treated as described in the legend to Fig. 3 and under “Experimental Procedures.” Lanes 1–19 represent samples withdrew from the reaction mixture at time intervals concentration a switch in the pathdetailed in the legend to Fig. 3. Panel A, control, prothrombinase assembled with plasma-derived factor Va in
the absence of peptide; panel B, prothrombinase in the presence of 0.2 M DYDYQ; panel C, prothrombinase in way for prothrombin activation
the presence of 2 M DYDYQ; panel D, prothrombinase in the presence of 4.2 M DYDYQ; panel E, prothrom- occurred, we studied the profile of
binase in the presence of 8.5 M DYDYQ; panel F, prothrombinase in the presence of 16.5 M DYDYQ. Gels were
prothrombin activation by prosubmitted to scanning densitometry as described under “Experimental Procedures,” and the rates of prothrombin consumption are reported in Table 1. For easier reading, the concentrations of peptide used in each thrombinase in the presence of
experiment are also shown under each panel (in M). Prothrombin-derived fragments are identified according increasing concentrations of pepto the legend of Fig. 3.
tide, and the data are presented in
Fig. 4. For simplicity, we have
focused on four characteristic fragments demonstrating cleavTABLE 1
age of prothrombin through either the pre2 pathway (fragment
Rate of activation of plasma-derived prothrombin by
prothrombinase in the presence of peptide DYDYQ
1䡠2 and prethrombin 2) or through the meizo pathway (Fig. 1,
Peptide concentration Plasma-derived prothrombina Fold decreaseb
fragment 1䡠2-A and B-chain), and the rates of prothrombin conM
moles consumed䡠s⫺1䡠mol factor Xa⫺1
sumption are reported in Table 1. In the presence of a mem0
8.2 ⫾ 0.6
brane surface, under the conditions employed (0.5 nM factor Xa
0.2
5.4 ⫾ 0.6
1.5
and 1 nM factor Va), and in the absence of peptide, prothrombin
4.2
3.2 ⫾ 0.4
2.6
8
0.87 ⫾ 0.3
9.4
consumption proceeds with a rate of 8.2 mol䡠s⫺1䡠mole factor
8.5
0.5 ⫾ 0.2
16.4
Xa⫺1 through the meizo pathway (Table 1). In the presence of 2
16.5
0.4 ⫾ 0.2
20.5
20
0.2 ⫾ 0.2
41
M peptide, fragment 1䡠2-A appeared readily and was quickly
a
The rates of prothrombin consumption were obtained following scanning densiconsumed following cleavage at Arg271. As a result, thrombin
tometry of the gels shown in Figs. 3 and 4. The final rate of prothrombin consumpformation occurred steadily as substantiated by the appearance
tion in the presence of prothrombinase assembled with plasma-derived factor Va
and various peptide concentrations was extracted following plotting of the data as
of the B chain of thrombin (Fig. 4, panels A–C). At a concentradescribed under “Experimental Procedures.”
b
tion of 4.2 M DYDYQ, both intermediates were observed (i.e.
Fold decrease is the ratio of the rate of prothrombin cleavage by prothrombinase in
the absence of peptide compared with the rate prothrombin activation by profragment 1䡠2-A and prethrombin 2) suggesting activation of
thrombinase in the presence of peptide.
prothrombin through both pathways (Fig. 4D). Under these
conditions, the rate of prothrombin consumption was only
DYDYQ. Almost complete inhibition of prothrombinase under decreased by 2.6-fold.
At 8.5 M peptide, there was a significant reduction in both
the conditions employed required 15 M DYDYQ.
We next assessed the effect of the pentapeptide on the path- prothrombin consumption (⬃16-fold; Table 1) and the rate of
way for prothrombin activation by gel electrophoresis. Fig. 3, thrombin formation (⬃60% by activity Fig. 2), which coincided
panel A, shows a control experiment and demonstrates that in with the complete disappearance of fragment 1䡠2-A and diminthe absence of peptide activation of prothrombin by prothrom- ished rate of appearance of the B chain of thrombin (Fig. 4E).
binase proceeds following initial cleavage at Arg320, through the Thus, when prothrombin is saturated with peptide, no initial
intermediate meizothrombin as confirmed by the appearance cleavage at Arg320 appears to occur; however, prothrombin
of fragment 1䡠2-A (meizo pathway). This fragment is then rap- activation still takes place following initial cleavage at Arg271
idly cleaved at Arg271 to produce thrombin. In the presence of (pre2 pathway), albeit with a slower rate. These data demon-
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thrombin formation is attenuated,
but thrombin formation occurs
through the alternate pathway; at
high peptide concentrations, both
prothrombin consumption by prothrombinase and thrombin formation are severely impaired. It thus
appears that although both cleavages are prone to inhibition by
DYDYQ, cleavage at Arg320 by prothrombinase is more susceptible to
peptide inhibition than cleavage at
FIGURE 5. Analysis of the activation of recombinant mutant prothrombin molecules by prothrombinase Arg271. The combined data suggest
in the absence and presence of DYDYQ. Mutant prothrombin molecules (300 nM) were preincubated with
buffer or a peptide solution and treated as described in the legend to Fig. 3 and under “Experimental Proce- that although inhibition of initial
dures.” Panel A, lanes 1–9 represent samples of the reaction mixture following incubation of prothrombinase cleavage at Arg320 by DYDYQ can
reconstituted with rMZ-II in the absence of DYDYQ, before (lane 1) or following 1, 4, 6, 10, 20, 30, 45, and 60 min be explained by the interference of
incubation with factor Xa, respectively; lanes 10 –18 represent samples of the reaction mixture following incubation of prothrombinase reconstituted with rMZ-II in the presence of 10 M DYDYQ, before (lane 10) or the peptide with the prothrombin
following 1, 4, 6, 10, 20, 30, 45, and 60 min of incubation with factor Xa. Panel B, lanes 1–9 represent samples of interactive site of factor Va heavy
the reaction mixture following incubation of prothrombinase reconstituted with rP2-II in the absence of
DYDYQ at times points identical to panel A, lanes 1–9; lanes 10 –18 represent samples of the reaction mixture chain, impaired initial cleavage at
271
by DYDYQ can be attributed
following incubation of prothrombinase reconstituted with rP2-II in the presence of 13 M DYDYQ at times Arg
points identical to panel A, lanes 10 –18. Positions of prothrombin-derived fragments are indicated at right as to the fact that high concentrations
detailed in the legend to Fig. 3. Molecular weight markers (M) are (from top to bottom): Mr 98,000, Mr 64,000, Mr
50,000, and Mr 36,000. Gels were submitted to scanning densitometry as described under “Experimental Pro- of peptide also interfere with the
cedures,” and the rates of prothrombin consumption are reported in Table 2.
prothrombin-binding site for factor
Xa that in turn is responsible for
accelerated
cleavage
of
prothrombin
at Arg271.
TABLE 2
To ascertain the effect of DYDYQ on each cleavage sepaRate of activation of recombinant prothrombin species by
prothrombinase
rately, we used recombinant prothrombin molecules that can
Peptide
only be cleaved at either Arg320 (rMz-II) or Arg271 (rP2-II) (Fig.
rMZ-II (cleavage at Arg320)a rP2-II (cleavage at Arg271)a
concentration
5). The data demonstrate that under similar experimental conM
moles consumed䡠s⫺1䡠mol factor Xa⫺1
ditions cleavage of rMZ-II is severely impaired, whereas cleav0
3.7 ⫾ 0.6
0.34 ⫾ 0.04
age of rP2-II does not appear to be affected by low concentra10
NSb
13
0.2 ⫾ 0.1
tions of DYDYQ. rMZ-II consumption was almost completely
c
35
NS
inhibited in the presence of 10 M DYDYQ. In contrast, cona
The rates of prothrombin consumption were obtained following scanning densitometry of the gels shown in Fig. 5. The final rate of prothrombin consumption in
sumption of rP2-II was only marginally reduced in the presence
the presence of prothrombinase assembled with plasma-derived factor Va and
of 13 M peptide (Table 2). Higher concentrations of DYDYQ
various peptide concentrations was extracted following plotting of the data as
(up to 35 M) were necessary to obtain significant inhibition of
described under “Experimental Procedures.”
b
NS, not significant consumption. The concentration of prothrombin varied from
the rate of cleavage of rP2-II by prothrombinase (Table 2).
300 nM at time 0 to 280.3 nM following 3 h of incubation with prothrombinase and
These data confirm our findings and demonstrate that cleavage
DYDYQ.
c
NS, not significant consumption. In separate experiments, using a higher concenat Arg320 is much more sensitive to inhibition by DYDYQ than
tration of DYDYQ, the concentration of prothrombin varied from 300 nM at time
is cleavage at Arg271, but at relatively high concentrations of
0 to 259.2 nM following 3 h of incubation with prothrombinase and DYDYQ.
DYDYQ, both cleavages can be substantially inhibited. Overall,
strate complete inhibition of the pathway of prothrombin acti- the data clearly demonstrate that the specific obstruction of the
vation characterized by initial cleavage at Arg320 by DYDYQ interaction of prothrombin with elements of prothrombinase
(meizo pathway). Substantial inhibition of thrombin formation, results in diminished thrombin production through the meizo
which correlates with decreased appearance of fragment 1䡠2, pathway. However, because prothrombin has two possible
prethrombin 2, and the B chain of thrombin, was observed in pathways for activation, the interaction of DYDYQ with prothe presence of 16.5 M peptide (Fig. 4F; Table 1). Under these thrombin favors the pre2 pathway.
Effect of DYDYQ on Prothrombin Activation by Factor Xa in
conditions, prothrombin activation occurs slowly and exclusively through the pre2 pathway. The rate of prothrombin con- the Absence of Factor Va—We next assessed the effect of the
sumption under these conditions was decreased by 20-fold. In peptide on the ability of membrane-bound factor Xa, in the
the presence of 20 M peptide, the rate of prothrombin con- absence of factor Va, to activate prothrombin. High concentrasumption was further decreased by 41-fold (Table 1). Finally, in tions of peptide were necessary to partially impair thrombin
the presence of very high concentrations of peptide (ⱖ100 M), formation under these conditions. However, complete inhibino significant prothrombin activation by prothrombinase was tion of thrombin formation could not be observed even in the
detected by gel electrophoresis (not shown). Overall, the data presence of high concentrations of DYDYQ (Fig. 6). Under
demonstrate a dual and differential effect of the peptide on both the experimental conditions used, the extent of inhibition of the
the rate and pathway for prothrombin activation by rate of thrombin formation by increasing concentrations of
prothrombinase; at low concentrations of peptide, meizo- DYDYQ, in several separate experiments, varied between 50
DECEMBER 22, 2006 • VOLUME 281 • NUMBER 51
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and 70%. These data demonstrate that DYDYQ has an effect on
prothrombin activation by membrane-bound factor Xa alone,
in the absence of factor Va. Analyses of the pattern of the time
course of prothrombin activation by membrane-bound factor
Xa in the absence of factor Va by gel electrophoresis demonstrated accelerated cleavage of prothrombin at Arg271 by membrane-bound factor Xa in the presence of the peptide (Fig. 7).
Similarly, whereas cleavage of rP2-II at Arg271 by membranebound factor Xa was significantly accelerated in the presence of
the peptide, proteolysis of rMZ-II did not appear to be consid-

FIGURE 6. Thrombin generation by membrane-bound factor Xa in the
absence of factor Va. Plasma-derived prothrombin (1.4 M) was incubated
with various concentrations of peptide shown on the x axis. The rate of thrombin formation by membrane-bound factor Xa alone, in the absence of factor
Va, was assessed as described under the “Experimental Procedures” and compared with the rate determined in a control reaction in the absence of peptide. The data represent the average of the results found in three independent measurements.

erably affected (Fig. 8). Scanning densitometry of the gels
shown in Figs. 7 and 8 provided a kinetic explanation for the
observed phenomenon. In the absence of peptide, membranebound factor Xa alone cleaved prothrombin and rP2-II with
similar rates (Table 3). Concentrations as high as 20 M
DYDYQ had minimal effect on rMZ-II consumption under the
conditions employed (i.e. in the absence of factor Va). In contrast, a significant acceleration of cleavage of plasma-derived
prothrombin and rP2-II by membrane-bound factor Xa alone
at Arg271 was observed in the presence of 24 M peptide (⬃50and 71-fold, respectively; see Table 3) resulting in accumulation
of prethrombin 2. Increasing the peptide concentration to 48
M had no further accelerating effect on the rate of prothrombin consumption (Table 3). It is interesting to note for comparison that the interaction of factor Va with factor Xa and prothrombin on a membrane surface results in a rate of
prothrombin consumption of 12 mol䡠s⫺1䡠mol Xa⫺1, which is
⬃200-fold faster than the rate of prothrombin consumption by
membrane-bound factor Xa alone. Similarly, the interaction of
DYDYQ with prothrombin results in a 50-fold increase in the
rate of prothrombin consumption. However, with factor Xa
and factor Va, prothrombin consumption results primarily in
thrombin formation, whereas with factor Xa and DYDYQ prothrombin consumption results in accumulation of prethrombin 2. Overall our data demonstrate that the interaction of
peptide DYDYQ with prothrombin has opposite effects on
membrane-bound factor Xa for cleavage of the substrate
depending on the incorporation of the cofactor into prothrombinase. In the presence of factor Va, the peptide decreases the
rate of substrate consumption by prothrombinase by selectively
inhibiting cleavage at Arg320 and directing factor Xa to the
alternate pathway characterized by initial cleavage at Arg271,
resulting in delayed thrombin formation. In the absence of factor Va, the peptide induces a significant acceleration of initial cleavage
at Arg271 by membrane-bound factor Xa alone, accelerating the rate of
prothrombin consumption resulting in accumulation of prethrombin
2.

FIGURE 7. Analysis of the activation of plasma-derived prothrombin by membrane-bound factor Xa
alone in the absence and presence of DYDYQ. Plasma-derived prothrombin (1.4 M) was preincubated with
buffer or a peptide solution. The mixture was subsequently incubated with PCPS vesicles and DAPA. The
reaction was started by the addition of factor Xa (2.5 nM). At selected time intervals, aliquots of the reactions
were withdrawn and treated as described under “Experimental Procedures.” Lanes 1–19 represent samples
from the reaction mixture before (0 min) the addition of factor Xa and 30 s, and 1, 3, 5, 7, 10, 12, 15, 20, 30, 45,
60, 75, 90, 105, 120, 150, and 180 min, respectively, following the addition of factor Xa. Panel A, activation by
membrane-bound factor Xa in the absence of peptide; panel B, activation by membrane-bound factor Xa in the
presence of 24 M DYDYQ. M represents the lane with the molecular weight markers (from top to bottom): Mr
98,000, Mr 64,000, Mr 50,000; Mr 36,000, and Mr 22,000. Prothrombin-derived fragments are identified according to the legend of Fig. 3. Other fragments are as follows: P1, prethrombin-1 (amino acid residues 156 –579),
and F1, fragment 1 (amino acid residues 1–155). Gels were submitted to scanning densitometry as described
under “Experimental Procedures,” and the rates of prothrombin consumption are reported in Table 3.
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DISCUSSION
Our data demonstrate that preincubation of prothrombin with a
peptide duplicating amino acid
sequence 695– 699 of factor Va,
prior to its inclusion in a mixture
containing prothrombinase, results
in inhibition of initial cleavage at
Arg320 by the enzyme (Fig. 9). During assembly of prothrombinase,
factor Va binds factor Xa, which in
turn is responsible for the catalytic
event per se. Thus, factor Va has a
dual effect within the complex, a
receptor effect and an effector
effect. Although the receptor effect
is easy to understand (binding to the
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which is not accessible to factor Xa
in the absence of factor Va nor in the
presence of both DYDYQ and factor
Va (Fig. 9B), needs extensive rearrangement and must rotate ⬃150°
around the Gly319–Gly324 hinge
points to be cleaved by factor Xa
(58). Collectively, the data suggest
that the interaction of prothrombin
with amino acids from factor Va
within prothrombinase may be part
of a requirement for the rearrangement of amino acids around the
320
321
bond in such a manFIGURE 8. Analysis of the activation of mutant prothrombin molecules by membrane-bound factor Xa Arg –Ile
alone in the absence and presence of DYDYQ. Mutant prothrombin molecules (1.4 M) were preincubated ner that it becomes accessible for
with buffer or a peptide solution and treated as described in the legend to Fig. 7. Panel A, lanes 1–9 represent
samples of the reaction mixture containing rMZ-II in the absence of DYDYQ, before (lane 1) or following 5, 15, efficient cleavage by factor Xa as
30, 60, 90, 120, 150, and 180 min of incubation with factor Xa, respectively; lanes 10 –18 represent samples of the part of prothrombinase.
reaction mixture following incubation of rMZ-II with 20 M DYDYQ, before (lane 10) or following 5, 15, 30, 60, 90,
Hirudin and Hir54 – 65(SO33) are
120, 150, and 180 min of incubation with factor Xa, respectively. Panel B, lanes 1–9 represent samples of the
reaction mixture containing rP2-II in the absence of DYDYQ at the same time points as in panel A, lanes 1–9; specific proexosite I ligands that
lanes 10 –18 represent samples of the reaction mixture containing rP2-II in the presence of 20 M DYDYQ at the interfere with the factor Va-prosame time points as in panel A, lanes 10 –18. Positions of prothrombin-derived fragments are indicated at right
as detailed in the legend to Fig. 3. Molecular weight markers (M) are (from top to bottom): Mr 98,000, Mr 64,000, thrombin interaction in vitro and in
Mr 50,000, and Mr 36,000. Gels were submitted to scanning densitometry as described under “Experimental whole plasma (28, 59). Nonetheless,
Procedures,” and the rates of prothrombin consumption are reported in Table 3.
it has been demonstrated that
Hir54 – 65(SO33) is impaired in its
inhibition of prothrombinase for prothrombin cleavage in the
TABLE 3
presence of phospholipid vesicles composed of 25% PS and 75%
Rate of cleavage of prothrombin molecules by membrane-bound
factor Xa alone in the absence of factor Va
PC (28, 60). Although the inhibitory potential of Hir54 – 65(SO33)
The rates of prothrombin consumption were obtained following scanning dension prothrombinase activity is partially recovered when similar
tometry of several gels analyzing prothrombin consumption by membrane-bound
factor Xa. Typical examples are illustrated in Figs. 7 and 8. The final rate of proexperiments are performed with phospholipid vesicles composed
thrombin consumption in the presence of membrane-bound factor Xa was
of 5% PS and 95% PC, complete inhibition of prethrombin 1 actiextracted following plotting of the data to a first-order exponential decay as
vation by fully assembled prothrombinase on phospholipid
described under “Experimental Procedures.”
vesicles composed of 25% PS and 75% PC was observed with
Peptide
Plasma-derived
rMZ-II
rP2-II
concentration Prothrombin (cleavage at Arg320) (cleavage at Arg271)
Hir54 – 65(SO33) (28). It has been also established that proteolytic
M
moles consumed䡠s⫺1䡠mol factor Xa⫺1
elimination of fragment 1 in bovine prothrombin results in the
0
0.06 ⫾ 0.03
0.08 ⫾ 0.022
0.014 ⫾ 0.005
elimination of the accelerating effect of the membrane surface
12
2 ⫾ 0.3
0.3 ⫾ 0.09
20
0.06 ⫾ 0.03
0.5 ⫾ 0.09
for initial cleavage at Arg320 by prothrombinase (56). The accu24
3.1 ⫾ 0.2
1 ⫾ 0.4
mulated data strongly suggest that binding of prothrombin to a
48
3 ⫾ 0.7
membrane surface rich in PS confers fragment 1 the capability
to interfere with the inhibitory effect of hirudin-derived pepmembrane-bound enzyme and formation of a binary complex), tides with (pro)exosite I, as well as the ability to regulate the
the effector effect is more intricate and requires a full consider- interaction of factor Va with prothrombin. It thus appears that
ation of the molecular dynamics involved in prothrombinase fragment 1 of prothrombin has a modulatory effect on the factor Va-prothrombin interaction. Data in support of this
complex assembly and function.
There is consensus in the literature that binding of pro- hypothesis include the demonstration that in the absence of
thrombin to prothrombinase involves the expression of an PCPS membranes amino acids from both the Gla domain and
exosite that is provided to the substrate upon the incorporation kringle 1 of prothrombin inhibit thrombin generation in the
of factor Va into the complex. One unanswered question is presence but not in the absence of factor Va, suggesting that
which molecule provides this extended exosite; is this exosite a amino acids from the NH2 terminus of prothrombin most likely
consequence of the exposure of a hidden portion of factor Xa regulate the factor Va-prothrombin interaction (61, 62).
alone, which is expressed upon its interaction with the cofacThe following has been well established: 1) fragment 1䡠2 of
tor? Is this exosite provided by elements of factor Va alone, or is prothrombin interacts with prethrombin 2 with high affinity
the exosite composed of discrete amino acids belonging to both (Kd⬃0.1–33 nM) through its fragment 2 component (37, 55, 63,
factor Va and factor Xa? The data presented herein confirm the 64); and 2) this latter interaction alone leads to a large accelerexistence of the factor Va-prothrombin interaction within pro- ation of the rate of cleavage at Arg320 of prethrombin 2 by fully
thrombinase first demonstrated approximately 30 years ago assembled prothrombinase (⬃150-fold increase in the second(57) and suggest that both factor Va and factor Xa provide for order rate constant in the presence of fragment 1䡠2 compared with
an exosite for prothrombin. Data from the crystal structure of the same reaction in the absence of fragment 1䡠2) (55). Our data
prethrombin-2 demonstrated that the Arg320–Ile321 bond, demonstrate that at low concentrations of pentapeptide, no signifDECEMBER 22, 2006 • VOLUME 281 • NUMBER 51
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icant decrease in the concentration of B chain of ␣-thrombin is
observed by gel electrophoresis because thrombin generation
occurs with approximately the same rate via both pathways.
Because fragment 1䡠2 accelerates cleavage at Arg320 by prothrombinase in prethrombin 2 in the pathway characterized by initial
cleavage at Arg271 (55, 63, 64), more DYDYQ peptide would be
necessary to sterically hinder the interaction resulting in
delayed ␣-thrombin generation through this pathway (Fig. 9C).
Membrane-bound factor Xa alone is capable of activating
prothrombin following sequential cleavages at Arg271 and
Arg320 resulting in slow generation of ␣-thrombin (Fig. 1, pathway I). Our present data show that although DYDYQ inhibits
initial cleavage at Arg320 by prothrombinase, the peptide accelerates significantly cleavage of prothrombin at Arg271 by membrane-bound factor Xa alone resulting in the accumulation of a
noncovalent complex composed of prethrombin 2 and fragment 1䡠2 (Fig. 9D). Because DYDYQ is a specific factor Va-dependent inhibitor of prothrombinase, these data suggest that
portions in/or around the factor Va-prothrombin interactive

site may also be involved in prothrombin activation by factor Xa
alone. Keeping in mind that fragment 1䡠2 accelerates significantly cleavage at Arg320 of prethrombin 2 by prothrombinase,
whereas DYDYQ does not have this effect and because the peptide does not interact with factor Xa, we can speculate that once
prothrombin is cleaved at Arg271 and fragment 1䡠2 interacts
with prethrombin 2, the role of factor Va within the complex is
exclusively reduced to the conversion of factor Xa in an enzyme
form (prothrombinase) that can efficiently cleave prethrombin
2 at Arg320. Consequently, results obtained with prethrombin 2
as a substrate for prothrombinase cannot be extrapolated and
compared with the data obtained using prothrombin as the
substrate for the enzyme. At this point we must note that the
possibility that pentapeptide DYDYQ might create long range
allosteric perturbations that in turn influence interactions distant from its site of binding cannot be excluded by our findings.
In line with all these findings, an alternative explanation for
the acceleration of the rate of cleavage at Arg320 in prethrombin
2 was provided by earlier studies (55, 65, 66). All experiments in

FIGURE 9. Schematic of the effect of DYDYQ on prothrombin cleavage in the presence and absence of factor Va. Panel A, initial cleavage of prothrombin
at Arg320 by prothrombinase results in the production of meizothrombin (meizo pathway). Subsequent cleavage of this intermediate at Arg271 produces
thrombin and fragment 1䡠2. This pathway is only observed in the presence of the nonenzymatic cofactor, factor Va. Initial cleavage of prothrombin at Arg271 by
membrane-bound factor Xa in the absence of factor Va results in the generation of fragment 1䡠2 and prethrombin 2 followed by subsequent cleavage at Arg320
resulting in thrombin formation (pre2 pathway). Panel B, preincubation of prothrombin with low concentrations of DYDYQ (shown by the filled octagon) results
in the inhibition of the meizo pathway and production of thrombin by prothrombinase through the pre2 pathway. Panel C, in the presence of high concentrations of DYDYQ (illustrated by the increased number of filled octagons), cleavage of prothrombin by prothrombinase through both pathways is significantly
inhibited, resulting in notably impaired thrombin formation. Panel D, preincubation of prothrombin with DYDYQ results in a significant acceleration of the rate
of cleavage at Arg271 by membrane-bound factor Xa alone, in the absence of factor Va, and accumulation of prethrombin-2. In this schematic the dotted arrows
represent kinetically slow reactions, and the heavy arrows depict kinetically fast reactions. The dotted molecules depict intermediates (meizothrombin or
prethrombin 2) or the final product (thrombin) that are generated with a very slow rate under the conditions described.
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these latter studies were performed with saturating phospholipid concentrations composed of 25% PS and 75% PC and with
prethrombin 2 as substrate for prothrombinase. These data
support the hypothesis of the existence of a cryptic exosite for
prothrombin docking exposed on membrane-bound factor Xa
upon its interaction with the cofactor. Hence, the major role of
factor Va in prothrombinase would be restricted solely to the
exposure of the cryptic exosite(s) on factor Xa. This interpretation was based on data showing no interaction of factor Va with
isolated fragment 2 (55) and from subsequent findings demonstrating inhibition of the acceleration of cleavage at Arg320 by
prothrombinase in prethrombin 2 by both active-site blocked
␣-thrombin and -thrombin (66). The latter thrombin derivative, which is produced following cleavage of the B chain of
␣-thrombin by chymotrypsin at Trp468 (sequence numbers in
prothrombin represent numbers obtained following consecutive numbering of the 579 amino acid residues in mature
human prothrombin) (67) is composed of two distinct fragments (68, 69) as follows: an NH2-terminal polypeptide that
contains ABE-I (1-thrombin), and the COOH-terminal portion of the B chain that contains ABE-II (2-thrombin). Using
these fragments from ␣-thrombin and prethrombin 2, Betz and
Krishnaswamy (66) identified 2-thrombin to be responsible
for the inhibition of prethrombin 2 cleavage by prothrombinase. Coincidentally, it has been reported that a pentadecapeptide representing amino acids 557–571 from the COOH terminus of the B chain of ␣-thrombin inhibits factor Xa activity
toward prothrombin in a factor Va-independent manner (70),
whereas a pentadecapeptide also contained within 2-thrombin and corresponding to amino acid residues 473– 487 of prothrombin inhibits prothrombinase activity as well, but in a factor Va-dependent manner (71). This latter group of amino acids
is immediately adjacent to (pro)exosite I as shown in the crystal
structures of human prethrombin 2 (58) and bovine meizothrombin desfragment 1 (72). Concurrent with all these findings, our data demonstrate that the pentapeptide DYDYQ has
an effect on membrane-bound factor Xa for cleavage of membrane-bound prothrombin both in the presence and absence of
factor Va. Collectively, the data imply that the amino acid
region spatially surrounding proexosite I in prothrombin most
likely has two contiguous interactive sites for the components
of prothrombinase as follows: a factor Va-interactive site that is
modulated by a portion of fragment 1 when prothrombin is
saturated with a lipid bilayer rich in PS, and a factor Xa-binding
site that is exposed (modulated) following incorporation of factor Va into prothrombinase and the interaction of prothrombin
with factor Va and/or fragment 1䡠2. Existence of the former has
been widely confirmed by direct binding assays (25, 28, 57, 61,
62, 73), by using prothrombin molecules mutated at specific
residues in (pro)exosite I (38, 39) and by our recent findings
demonstrating competitive inhibition of prothrombinase by
DYDYQ (40), whereas direct evidence for the existence of the
latter was provided by experiments using deletion mutants of
prothrombin (74), monoclonal antibodies to fragment 2 (75),
and synthetic peptides from fragment 2 (76, 77).
In conclusion, our data provide a logical explanation for
many apparently conflicting results and, put in the context of
the literature, demonstrate that binding of the cofactor to both
DECEMBER 22, 2006 • VOLUME 281 • NUMBER 51

prothrombin and factor Xa is required for optimum prothrombinase function under physiological conditions. Bearing all
these qualifications in mind, the data presented herein are consistent with the interpretation that the leading mechanism by
which factor Va physiologically increases the catalytic efficiency of factor Xa within prothrombinase is by binding both
enzyme and substrate, and altering the structure and accessibility about the scissile bonds. Thus, following incorporation
into prothrombinase, factor Va actively guides factor Xa for
efficient prothrombin catalysis.
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